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Background: Obstructive Sleep Apnea (OSA) has been observed to be common among people living with HIV/AIDS
(PLWHA). Sleep scales can be used to screen patients at increased “risk” of OSA who can benefit from polysomnography.
This study therefore sought to generate preliminary data on this often unattended complication of HIV Infection in
Cameroon.
Methods: A case control study carried out at the Yaoundé Central Hospital in which 82 participants were enrolled: 39
PLWHA age- and sex-matched with 43 controls. The Berlin sleep questionnaire was used to assess the likelihood of OSA
in both groups.
Results: Participants were aged 20 to 59 years with a mean age of 34.27 ± 9.29 (35.72 ± 10.09 and 32.92 ± 8.41
respectively for cases and controls, p = 0.180). Cases (PLWHA) compared to controls had higher likelihood of OSA (43.6%
versus 14.0%, AOR 3.93 95% CI 1.12–13.80 on adjusting for socioeconomic status, depression and smoking) as well as 10
times higher rates of daytime somnolence (23.1% versus 2.3%, p = 0.005). Significant differences were found between
PLHWA at “risk” of OSA and those without only with regards to rate of compliance to Highly Active anti-Retroviral
Therapy (HAART), and mean abdominal and waist circumferences.
Conclusions: The likelihood of obstructive sleep apnea (OSA) in PLHWA is higher than in HIV negative
controls. Integration of screening for OSA in HIV/AIDS care with the aid of sleep scales would permit timely
diagnosis and management and reduce the incidence of chronic cardiorespiratory co-morbidities in PLWHA.
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Obstructive sleep apnea (OSA), results from repeated epi-
sodes of upper airway obstruction during sleep caused by
collapse of the pharyngeal airway (Somers et al. 2008). Al-
terations in upper airway anatomy as well as disturbances
in neuromuscular control play an important role in the
pathogenesis of OSA (McGinley et al. 2008; Isono et al.
1999; Smith et al. 1988; Gupta et al. 2010). The disease is
characterized by periodic cessation of breathing during* Correspondence: mbongeta@yahoo.fr
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brief arousal to reinitiate breathing (Taibi 2013). OSA is
usually associated with obesity (Gupta et al. 2010; Resta
et al. 2001) and the onset of sleep apnea frequently follows
a marked increase in body weight (Smith et al. 1988). How-
ever, obesity alone is not essential for the development of
OSA (Resta et al. 2001; Lo et al. 1998; Joy et al. 2008; Lo Re
et al. 2006; Dorey-Stein et al. 2008; Epstein et al. 1995).
OSA has been observed by some authors to be common
among persons living with HIV/AIDS (PLWHA) (Taibi
2013; Lo Re et al. 2006; Dorey-Stein et al. 2008; Epstein
et al. 1995). In this group of persons, body composition ab-
normalities such as subcutaneous fat wasting, central fat ac-
cumulation (Brown et al. 2010), and adenotonsillarle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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to the viral infection and Highly Active Anti-Retroviral
Therapy (HAART) (Lo et al. 1998). Among non-obese
PLWHA visceral fat has been found to be increased com-
pared to HIV negative controls (Joy et al. 2008); fat accu-
mulations are common along the cervical and dorsal
regions of the bodies of PLWHA (Lo et al. 1998). Sleep
scales can be used in clinical settings to screen patients
likely to suffer from OSA who can be sent early to sleep la-
boratory for confirmatory polysomnography.
The impact of OSA on health cannot be over em-
phasized given the increased morbidity (Gupta et al.
2010) and mortality it is associated as a results of
cardiovascular and metabolic complications in par-
ticular and impairment in quality of life in general
(Somers et al. 2008; Brown et al. 2010; Kendzerska
et al. 2014; Budhiraja and Quan 2005). Despite its
known impact, data on this subtle but severe compli-
cation of HIV infection in Cameroon is inexistent.
It was therefore necessary to assess the “risk” of OSA
among PLWHA in Cameroon in order to generate pre-
liminary data from which initiatives to raise awareness
and promote early diagnosis and management of OSA in
this population can be started. This study sought there-
fore to study this often unattended-to complication of
HIV Infection in Cameroon with the aid of the Berlin
Questionnaire sleep scale, in a population of PLWHA
compared with their HIV negative peers.Methods
Study design
The study was a hospital-based case–control study con-
ducted over a period of 8 months in 39 consenting
PLWHA age- and sex-matched with 43 controls.Study setting
The study was carried out in Yaoundé, the cosmopolitan
capital city of Cameroon, specifically at the HIV/AIDS
Treatment Centre and Neurology Service of the Yaoundé
Central Hospital.
The Yaoundé Central Hospital is a government run ter-
tiary health facility with a bustling HIV/AIDS outpatient
department (the largest in the country), which serves
PLWHA from Yaoundé and its environs. In addition, the
Neurology Department of this hospital has a sleep labora-
tory that supports this kind of study.
Ethical approval was obtained from the review board of
the Faculty of Medicine and Biomedical Sciences (FMBS)
of the University of Yaoundé 1 and administrative clear-
ance from the directorate of the Yaoundé Central Hos-
pital. Information collected from study participants and
patient files were coded and confidentially handled.Study participants
Participants were adults aged 20 to 59 years (Khassawneh
et al. 2009) with a confirmed HIV-positive serology (for
cases) attending the HIV/AIDS Treatment Centre of the
study site and clinically stable enough to participate in the
study. Were excluded all PLWHA known to be obese
(BMI ≥30 kg/m2) prior to HIV diagnosis as well as preg-
nant women, demented patients, people with abnormal
sleep-wake cycles due to night-shift work and all individ-
uals who were on or had taken sleep inducing medica-
tions, or stimulants during the three months preceding
the study.
Controls were selected from among other patients,
care takers and others who visited the hospital and were
confirmed HIV-negative at the time of the study.
Participants were contacted and recruited by the study
investigators consecutively as they presented at the treat-
ment center. The study objectives and procedures were
explained to participants and informed consent obtained.
A total of 82 participants were enrolled for the study.Instruments
Socio-demographic and clinical data of study participants
were collected through interviews with the aid of a pre-
tested pre-structured questionnaire. Data collected in-
cluded age (as at last birthday), sex, employment status,
religion, monthly income bracket, highest level of formal
education attained, cigarette smoking status, number of
check-up and unwell visits to health care provider during
the previous three months. PLWHA had their highly ac-
tive antiretroviral treatment status, regimen and duration
probed as well. All study participants benefitted from a
complete physical examination with focus on neurological
examination and anthropometric measurements.
The likelihood (“risk”) of OSA was assessed with the aid
of the Berlin Questionnaire and daytime sleepiness with
the aid of the Epworth Sleepiness Scale (ESS). The Berlin
questionnaire was designed to screen for sleep apnea in
primary care population and stratifies patients into low or
high “risk” (Netzer et al. 1999). It has high reliability
(Cronbach α 0.86–0.92), and a high positive predictive
value in identifying ambulatory OSA cases at high “risk”
of sleep apnea (Netzer et al. 1999).Study variables
HIV case: Confirmed by ELISA and dichotomized as
positive or negative.
HIV serotype: Confirmed by laboratory analysis of
blood samples of HIV positive cases; nominally grouped
into HIV1, HIV 2, and HIV 1&2.
HIV clinical staging: Grouped into 4 clinical stages
with respect to the WHO 2006 clinical staging algorithm
(based on clinical signs and symptoms) (World Health
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tion algorithm (CDC 2014).
HAART use and regimen: Use of HAART was dichoto-
mized as a yes or no as reported by the patient and con-
firmed by clinical records. Regimen type was nominally
categorized.
Age at HIV diagnosis and disease duration: Age in
years at which patient reported (confirmed by diagnosis
report) he or she was diagnosed HIV positive from
which disease duration was deducted after comparing




N 43 52.4 39
Sex
Male 19 44.2 13
Female 24 55.8 26
Age (years)
Mean ± SD 32.92 ± 8.41 35.72 ±
20–29 16 37.2 14
30–39 16 37.2 11
≥40 11 25.6 14
Employment status
Unemployed 12 27.9 11
Employed 31 72.1 28
Level of education
Primary 9 20.9 7
Secondary 19 44.2 29
Tertiary 15 34.9 3
Marital status 0.0
Single 28 65.1 24
Married 15 34.9 12
Widow(er) 0 0.0 3
Socioeconomic status (SES)
Low SES 23 53.5 19
Middle SES 19 44.2 19
High SES 1 2.3 1
Smokes
Yes 2 4.7 1
No 41 95.3 38
Alcohol consumption
Yes 19 44.2 22
No 24 55.8 17months respectively then categorized ordinally as shown
on Table 2.
Number of routine visits to physician and number of
unwell visits to physician during previous three
months: As reported by study participants and con-
firmed by patient records. Assessed as continuous
data and then ordinally categorized as shown on
Table 2.
Compliance to HAART treatment during the previous
month was assessed dichotomously as yes or no. Cases







33.3 0.314 32 39.0
66.7 50 61.0
10.09 0.180 34.27 ± 9.29
35.9 0.541 30 36.6
28.2 27 32.9
35.9 25 30.5
28.1 0.003 23 28.0
71.8 59 72.0




61.5 0.244 52 63.4
30.8 27 32.9
7.7 3 3.7
48.7 0.911 42 51.2
48.7 38 46.3
2.6 2 2.4
2.6 1.00 3 3.7
97.4 79 96.3
56.4 0.269 41 50.0
43.6 41 50.0
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than 7 times in a month.
Risk of OSA: Dichotomized as “risk” or “no risk” of
OSA based on responses to items on the Berlin
questionnaire.
Daytime sleepiness: Ordinally categorized with re-
spect to scores got on assessment with the Epworth
sleep scale (ESS): score of 1–14 (restful sleep and no
daytime sleepiness), score ≥15 (excessive daytime
somnolence).
Data analyses
Data collected was entered into an excel sheet and
uploaded for analyses unto version 20 of the Statistical
Package for Social Sciences (SPSS 20). Continuous data
are presented as means ± SD as well as ordinate categor-
ies, and non-continuous data as proportions (%).
Strengths of associations between categorical variables





Mean ± SD 25.17 ± 4.34
Underweight (<18.5) 1 2.3
Normal BMI (18.5–25.00) 25 58.1
Overweight (25.01–29.99) 10 23.3
Obese (≥30.00) 7 16.3
Weight gain (kg) 0.38 ± 5.20
Neck circumference (cm) 36.53 ± 3.00
Abdominal circumference (cm) 89.27 ± 12.80
Waist circumference (cm) 86.28 ± 13.60
Hip circumference (cm) 100.35 ± 13.80
Waist Hip Ratio 0.86 ± 0.08
Pulse (/min)




Systolic (Mean ± SD) 119.51 ± 14.21






Abnormal 0 0.0proportions determined with the aid of chi-squared tests
(X2). Differences between means of continuous variables
between groups were done with the aid of t-tests. All
test statistics are two-sided and considered statistically
significant at p < 0.05.Results
Socio-demographic characteristics of participants
A total of 82 participants were enrolled into the study
(39 cases and 43 sex and age matched controls). Partici-
pants were as young as 20 and as old 59 years with a
mean age of 34.27 years (SD 9.29). But for employment
status and level of education, there was no significant
difference between the socio-demographic characteris-
tics of cases and controls (Table 1). More cases were un-
employed than controls (5.1% versus 0.0%, p = 0.003)
and fewer had attained tertiary levels of education (7.7%





n % N %
25.23 ± 4.48 0.955 25.20 ± 4.38
1 2.6 0.928 2 2.5
21 55.3 46 56.8
11 28.9 21 25.9
5 13.2 12 14.8
−1.83 ± 6.10 0.104 −0.68 ± 5.72
35.74 ± 4.70 0.360 36.16 ± 3.89
86.30 ± 12.19 0.364 87.93 ± 12.52
85.58 ± 11.98 0.808 85.95 ± 12.79
100.05 ± 11.57 0.918 100.21 ± 12.73
0.85 ± 0.06 0.712 0.86 ± 0.07
79.19 ± 16.57 0.086 76.46 ± 11.04
22 81.5 0.222 45 73.8
5 18.5 16 26.2
121.61 ± 17.77 0.561 120.47 ± 15.86
75.42 ± 16.57 0.981 75.46 ± 13.42
8 22.2 0.338 14 17.7
28 77.8 65 82.3
36 92.3 0.103 79 96.3
3 7.7 3 3.7
Table 3 HIV disease characteristics of the cases
N %
39 47.6
Age at diagnosis (years)
Mean ± SD 32.26 ± 8.94
20–24 9 23.7
≥25 29 76.3
Disease duration since diagnosis
Mean ± SD (months) 44.61 ± 50.12
≤6 months 14 36.8
<6 months 24 63.2




Stage 1 26 68.4
Stage 2 3 7.9
Stage 3 7 18.4






Routine check-ups in last 3 months
Mean ± SD 1.00 ± 1.33
None 20 54.1







HAART duration since onset
Mean ± SD (months) 47.76 ± 44.71
<6 months 4 23.5
≥6 months 13 76.5
HAART protocol type
1st line 13 92.9
2nd line 1 7.1
HIV complications during 3 months preceeding study
At least one 2 5.4
None 35 94.6
Presence of other concurrent disease
At least one 5 13.5
None 32 86.5
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On clinical assessment (Table 2) anthropometric mea-
surements, blood pressure and pulse were not signifi-
cantly different between the two groups.
HIV disease characteristics and HAART
Almost a quarter (23.9%) of study cases were diagnosed
positive with HIV at the age of under 25 years, three
quarters (29; 76.2%) had lived with the disease for at
least 6 months and two-thirds on HAART (24; 63.2%) of
which half (54.1%) for at least 6 months (Table 3). 42.9%
of cases on 1st line HAART were on a regimen with
Efavirenz (Table 3).
HIV-AIDS disease history of cases and disease follow-up
Cases had a mean age of 32.26 ± 8.94 years and had been
diagnosed HIV positive for more than three years (mean
duration of 44.61 ± 50.12 months); Table 3. Two thirds
(63.2%) were on HAART, mainly (92.1%) 1st line (Table 3).
Snoring habits and assessment of the “risk”/likelihood of
OSA in cases and controls
Cases (PLWHA) compared to controls had higher rates of
“risk” (moderate as well as high) of OSA (43.6% versus
14.0%, OR 4.77 95% CI 1.64–13.89 and AOR 3.93 95% CI
1.12–13.80 on adjusting for socioeconomic status, depres-
sion and smoking) and consequently had 10 times higher
rates of daytime somnolence (Table 4).
HIV disease characteristics, and anthropometric and
clinical parameters in PLWHA with and those without
“risk” of OSA
With respect to OSA and HIV disease characteristics and
management, cases with “risk” (moderate as well as high
risk) of OSA differed significantly from those without,
only with regards to compliance to HAART. The rate of
compliance to HAART was higher in HIV cases with
“risk” of OSA compared to HIV cases without (100.0%
versus 60% respectively, p = 0.034); Table 5. With regards
to anthropometry, significant differences were found with
regards to abdominal and waist circumferences (Table 6).
Discussion
These preliminary findings are part of a study which
sought to generate data on disordered sleep an often un-
attended complication of HIV Infection. Focus was on ob-
structive sleep apnea (OSA) whose likelihood was assessed
with the aid of the Berlin Questionnaire sleep scale in
people living with HIV/AIDS (PLWHA) compared to
matched HIV negative controls.
Cases (PLWHA) compared to controls had higher
“risk” (moderate as well as high) of OSA (43.6% versus
14.0%, p = 0.003 and AOR 3.98 95% CI 1.14–13.99 on
adjusting for socioeconomic status, depression and
Table 4 Snoring habits, and rates of ‘risk’ of OSA and daytime somnolence




sampleNegative (Controls) Positive (Cases)
N % n % N %
N 43 39 82
Snoring
Yes 11 25.6 10 25.6 1.00 21 25.6
No 32 74.4 29 74.4 61 74.4
Risk of OSA
No risk 37 86.0 22 56.4 0.003 59 72.0
Moderate Risk 6 14.0 12 30.8 18 22.0
High risk 0 0.0 5 12.8 5 6.0
Daytime somnolence
Yes 1 2.3 9 23.1 0.005 10 12.2
No 42 97.7 30 76.9 72 87.8
OSA Obstructive Sleep Apnea
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of other authors in other settings who demonstrated that
compared with HIV negative controls, obstructive sleep
apnea (OSA) is more common in PLWHA (Taibi 2013;
Lo Re et al. 2006; Dorey-Stein et al. 2008; Epstein et al.
1995). In this group of persons, body composition ab-
normalities (Brown et al. 2010), and adenotonsillar
hypertrophy (Epstein et al. 1995) are common; partly
due to the viral infection and Highly Active Anti-
Retroviral Therapy (HAART) (Lo et al. 1998).
The higher likelihood of OSA this study observed
in PLWHA compared to their HIV negative peers
was despite the fact that the former did not differ
significantly from the latter (Table 2) with respect to
aspects related to externally observable fat accumula-
tion: BMI, neck, waist and abdominal circumferences
and lipodystrophy known predisposing factors of OSA
in HIV negative persons. With the aid of dual-energy
X-ray absorptiometry and computed tomography,
PLWHA without clinical evidence of lipodystrophy
have been shown to have significantly greater percent-
age of total body fat in the trunk and significantly
lower percent of body fat in the extremities compared
to HIV negative controls (CDC 2014). These, physical
examination misses.
Vgontzas AN and collaborators in 2000 (Kosmiski
et al. 2003), demonstrated that sleep apnea patients
had a significantly greater amount of visceral fat com-
pared to obese controls and that indices of sleep dis-
ordered breathing (SDB) were positively correlated
with visceral fat, and not with BMI, total and subcuta-
neous fat. Another author (Brown et al. 2010) however
showed that BMI, waist circumference, and neck cir-
cumference have better predictive value for moderate-
severe SDB in HIV uninfected men compared to HIV-infected men, and had no value among HIV-infected
men not receiving HAART. Among this latter group
(HIV-infected men not on HAART), systemic inflam-
mation is thought to contribute to the pathogenesis of
SDB (Brown et al. 2010).
With respect to OSA and HIV disease characteristics
and management, cases with “risk” of OSA in our study
differed significantly from those without, only with
regards to compliance to HAART (Table 5). Compliance
to HAART favors fat redistribution in PLWHA: visceral
as well as lipodystrophy (Lo Re et al. 2006; Kosmiski
et al. 2003). Brigham and collaborators (McNicholas
2009) demonstrated that PLWHA not on HAART with
moderate to severe OSA have high circulating levels of
inflammatory markers especially TNF-alpha, compared
to those with no-to-mild OSA after adjustment for age,
race, smoking status, obstructive lung disease and BMI.
Within this group, the association of high TNF-alpha
concentrations with moderate-severe OSA was inde-
pendent of CD4 cell count and viral load. Factors that
reduce the inflammation associated with HIV infection
such as HAART initially would reduce the occurrence of
OSA in these patients. This improvement over time
wanes due to fat redistribution secondary to HAART.
As was observed when compared with the HIV
negative controls, HIV cases with “risk” of OSA did
not show significant differences when compared HIV
cases without risk of OSA with regards to mean BMI
and neck circumferences (Table 6). Significant differ-
ences were however found between the two groups
with respect to indices of abdominal obesity (waist
and abdominal circumferences, Table 6). In the case
of abdominal circumference, accumulation of fat in
the abdominal wall may reduce respiratory effort and
predispose to sleep apnea. Waist circumference on its





No “risk” of OSA “Risk” of OSA
N % N % N %
HIV genotype
HIV1 8 42.1 5 31.3 0.679 13 37.1
HIV2 1 5.3 2 12.5 3 8.6
HIV1+2 0 0.0 1 6.3 1 2.9
Undetermined genotype 10 52.6 8 50.0 18 51.4
Age at diagnosis (years)
Mean ± SD 34.55 ± 9.84 37.24 ± 10.51 0.416 34.27 ± 9.29
20–24 6 28.6 3 17.6 0.425 9 23.7
≥25 15 71.4 14 82.4 29 76.3
Duration since diagnosis
<= 6 months 8 38.1 6 35.3 0.717 14 36.8
>6 months 13 61.9 11 64.7 24 63.2
CD4 count (count/mm3)
Mean ± SD 387.10 ± 150.58 490.33 ± 107.96 0.299 410.92 ± 144.90
<350 3 30.0 0 0.0 0.528 3 23.1
≥350 7 70.0 3 100.0 10 76.9
WHO disease stage
Stage 1 15 71.4 11 64.7 0.930 26 68.4
Stage 2 2 9.5 1 5.9 3 7.9
Stages 3–4 4 19.1 5 29.4 9 23.7
Routine check-ups in last 3 months
None 10 50.0 10 58.8 0.591 20 54.1
At least 1 10 50.0 7 41.2 17 45.9
Patient on HAART
Yes 8 38.1 6 35.3 1.00 14 36.8
No 13 61.9 11 64.7 24 63.2
HAART duration
Mean ± SD 61.11 ± 51.59 32.75 ± 32.27 0.201 47.76 ± 44.71
<6 months 2 22.2 2 25.0 1.00 4 23.5
≥6 months 7 77.8 6 75.0 13 76.5
HAART protocols 0.0 0
1st line 8 100.0 5 83.3 0.429 13 92.9
2nd line 0 0.0 1 16.7 1 7.1
Compliance last 30 days
Compliant 4 40.0 6 100.0 0.034a 10 62.5
Not complaint 6 60.0 0 0.0 6 37.5
Complications in last 3 months
None 0 0.0 2 11.8 0.204 2 5.4
At least one 20 100.0 15 88.2 35 94.
Presence of other concurrent diseases
At least one 2 10.0 3 17.6 0.644 5 13.5
None 18 90.0 14 82.4 32 86.5
asignificant difference. OSA Obstructive Sleep Apnea
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Table 6 Occurrence of snoring and means of anthropometric and blood pressure parameters in PLWHA cases with OSA compared
to those without




sampleNo risk of OSA Risk of OSA
Snores
No 21 (95.5) 8 (47.1) 0.001 29 (74.4)
Yes 1 (4.5) 9 (52.9) 10 (25.6)
Means ± SD
Neck circumference (cm) 35.05 ± 4.92 36.69 ± 4.35 0.294 35.74 ± 4.70
BMI (kg/m2) 24.54 ± 3.82 26.17 ± 5.24 0.273 25.23 ± 4.48
Abdominal circumference (cm) 81.80 ± 9.94 91.92 ± 12.80 0.029a 86.30 ± 12.19
Waist circumference (cm) 81.86 ± 12.38 90.69 ± 9.57 0.023a 85.58 ± 11.98
Waist hip ratio 0.84 ± 0.07 0.87 ± 0.04 0.114 0.85 ± 0.06
Systolic blood pressure (mm Hg) 123.30 ± 18.13 119.50 ± 17.66 0.532 121.61 ± 17.77
Diastolic blood pressure (mm Hg) 75.85 ± 15.63 74.88 ± 18.19 0.809 75.42 ± 16.57
Pulse (/min) 76.60 ± 12.09 82.42 ± 9.80 0.190 79.19 ± 16.57
asignificant difference. OSA Obstructive Sleep Apnea, PLWHA Persons living with HIV/AIDS
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marker of visceral obesity in PLWHA (Kapur et al.
1999). Further studies need to be done on the contri-
bution of waist circumference in the occurrence of
OSA in PLWHA.
Our study had some limitations. OSA was assessed with
a questionnaire and was not confirmed with Polysomno-
graphy (PSG), the gold standard for the diagnosis of OSA.
However, we used a standardized instrument (the Berlin
Questionnaire) that has been validated and found to be re-
liable. Also, we did not clinically diagnose adenotonsillar
hypertrophy known to play a role in the development of
OSA in HIV positive persons (Epstein et al. 1995; McNi-
cholas 2009). The study sample size as well as not all
PLWHA having had a recent CD4 count at time of study
as well as viral load limited comparisons with regards to
disease progression and viral genotype.
Given the socio-economic burden of untreated OSA
(Kapur et al. 1999), its association with HIV/AIDS (a pan-
demic most prevalent in sub-Saharan African settings like
ours) and role of HAART (which more and more
PLWHA in out setting now have access to) in HIV disease
and OSA occurrence, it is relevant to integrate as part of
care of PLWHA, routine screening to identify those at risk
of OSA with the aid of sleep scales. Given the peculiarities
of the pathophysiology OSA in PLWHA discussed above,
unlike in HIV negative subjects, all PLWHA should be
screened including those without obvious body fat
changes and obesity and those not yet on HAART.
Early identification of the risk of OSA in PLWHA would
go a long way to spur referrals for polysomnography, timely
management and contribute to the reduction of theincidence of cardiorespiratory co-morbidities in HIV/AIDS,
now a chronic condition in low resource settings like ours
thanks to access to HAART. This however has to be sup-
ported by advocacy actions towards policy makers and duty
bearers, for more sleep clinics to be set-up so as to ensure
supply meets the increased demand which would be gener-
ated by raised awareness.Conclusion
The “risk”/likelihood of obstructive sleep apnea (OSA) in
people living with HIV/AIDS is higher than in HIV nega-
tive controls. Unlike HIV negative persons this risk ap-
pears not to be linked to externally obvious markers of
obesity. Integration of screening for OSA with the aid of
sleep scales (validated in our setting against gold standard
polysomnography) in HIV/AIDS care will permit timely
diagnosis and management which would go a long way to
reduce the incidence of chronic cardiorespiratory co-
morbidities in PLWHA.
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